{"trials": {"1": {"nct_id": "NCT05945147", "drug_name": "Ketamine", "intervention_type": "DRUG", "drug_description": "An escalating dose of ketamine (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.743782", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.743835", "retry_count": 0}}, "2": {"nct_id": "NCT05945147", "drug_name": "Midazolam", "intervention_type": "DRUG", "drug_description": "A constant dose of midazolam (0.04 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.744511", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.744521", "retry_count": 0}}, "3": {"nct_id": "NCT05945147", "drug_name": "Normal Saline", "intervention_type": "DRUG", "drug_description": "An escalating dose of normal saline (0.15 to 0.4 mg/kg/hr) will be administered as 4-hour infusions over 5 consecutive days", "phase": "PHASE2", "overall_status": "WITHDRAWN", "why_stopped": "Lack of funding", "title": "Ketamine and Midazolam Infusions for CRPS: Feasibility Study", "start_date": "2099-01-01", "completion_date": "2099-05-31", "sponsor": "Stanford University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.744837", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.744842", "retry_count": 0}}, "16": {"nct_id": "NCT06940570", "drug_name": "PCA Alone (SOC)", "intervention_type": "DRUG", "drug_description": "PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).", "phase": "PHASE3", "overall_status": "SUSPENDED", "why_stopped": "Study is closed with the IRB due to no funding. May resume once funding is obtained.", "title": "Methadone as an Alternative Treatment for Children Underdoing HSCT", "start_date": "2028-01-01", "completion_date": "2029-08-01", "sponsor": "University of Texas Southwestern Medical Center", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.749086", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.749093", "retry_count": 0}}, "17": {"nct_id": "NCT06940570", "drug_name": "PCA plus methadone (Experimental)", "intervention_type": "DRUG", "drug_description": "This study is novel. There are no other interventions to distinguish in this or another study.", "phase": "PHASE3", "overall_status": "SUSPENDED", "why_stopped": "Study is closed with the IRB due to no funding. May resume once funding is obtained.", "title": "Methadone as an Alternative Treatment for Children Underdoing HSCT", "start_date": "2028-01-01", "completion_date": "2029-08-01", "sponsor": "University of Texas Southwestern Medical Center", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.749804", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.749811", "retry_count": 0}}, "18": {"nct_id": "NCT06752876", "drug_name": "CB-010", "intervention_type": "DRUG", "drug_description": "CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion", "phase": "PHASE1", "overall_status": "WITHDRAWN", "why_stopped": "Sponsor Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs", "title": "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)", "start_date": "2027-12-31", "completion_date": "2029-04-30", "sponsor": "Caribou Biosciences, Inc.", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.750415", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.750421", "retry_count": 0}}, "25": {"nct_id": "NCT05452408", "drug_name": "Antitumor B KAC", "intervention_type": "DRUG", "drug_description": "ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.", "phase": "PHASE1", "overall_status": "WITHDRAWN", "why_stopped": "Study abandoned.", "title": "Antitumor-B KAC PK Study", "start_date": "2026-12-31", "completion_date": "2027-12-31", "sponsor": "Medical College of Wisconsin", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.753082", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.753083", "retry_count": 0}}, "35": {"nct_id": "NCT04585711", "drug_name": "Etanercept Optimal dosing", "intervention_type": "DRUG", "drug_description": "Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.", "phase": "PHASE1", "overall_status": "WITHDRAWN", "why_stopped": "Funding expired", "title": "Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis", "start_date": "2026-07-01", "completion_date": "2027-02-28", "sponsor": "Duke University", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.756054", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.756056", "retry_count": 0}}, "45": {"nct_id": "NCT05683574", "drug_name": "cyclobenzaprine hydrochloride + etoricoxib placebo", "intervention_type": "DRUG", "drug_description": "Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul\u00ae) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.", "phase": "PHASE3", "overall_status": "WITHDRAWN", "why_stopped": "Change in study strategy.", "title": "Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil", "start_date": "2026-05-30", "completion_date": "2028-02-28", "sponsor": "Eurofarma Laboratorios S.A.", "enrichment_status": {"stage1_extracted": "2025-11-14T00:19:39.759328", "stage2_targets": "pending", "stage2_ppi": "pending", "stage2_failure_details": "pending", "stage3_llm_analysis": "pending", "last_updated": "2025-11-14T00:19:39.759331", "retry_count": 0}}}}